PCSA - Processa Pharmaceuticals Innovative Cancer Treatment Demonstrates Higher Efficacy at Lower Doses Over Capecitabine | Benzinga
Processa Pharmaceuticals Inc (NASDAQ: PCSA) provides an interim analysis from its Phase 1b Next Generation Capecitabine (NGC-Cap) study.
Thus far in the Phase 1b study, patients have received doses of NGC-Cap ranging from 75 mg once a day to 225 mg twice daily, significantly less than the 1,600 mg to 2,500 mg twice-a-day dose administered for FDA-approved capecitabine.
These much lower doses for NGC-Cap result in 5-FU exposure up to 10 times greater than the higher FDA-approved capecitabine doses due to NGC-Cap's unique metabolic ...